The Association Between Reversion of Prediabetes to Normoglycemia and Incident Cardiovascular Disease and Mortality: A Systematic Review and Meta-Analysis.
Reversion from prediabetes to normoglycemia is associated with significant reductions in cardiovascular events and cardiovascular mortality, supporting early identification and management of prediabetes as a cardiovascular prevention strategy.
Abstract
Background
Prediabetes affects approximately 470 million adults worldwide and is an established risk factor for cardiovascular disease. Whether reversion from prediabetes to normoglycemia reduces cardiovascular risk remains uncertain. We conducted a systematic review and meta-analysis to quantify this association with major cardiovascular events, cardiovascular mortality, and all-cause mortality.
Methods
We searched PubMed, Embase, CENTRAL, Web of Science, and Scopus through February 2026 for cohort studies and post-hoc analyses of randomized trials comparing cardiovascular outcomes in adults who reverted from prediabetes to normoglycemia versus persistent prediabetes. Hazard ratios were pooled using a DerSimonian-Laird random-effects model, with Hartung-Knapp-Sidik-Jonkman (HKSJ) sensitivity analysis. Heterogeneity was assessed using I2. Publication bias was evaluated using Egger's test.
Results
Seven studies (71,143 participants; follow-up 2-30 years) were included. Reversion to normoglycemia was associated with significantly lower composite cardiovascular events (HR 0.72, 95% CI 0.57-0.90; P = 0.004; I2 = 76.1%) and cardiovascular mortality (HR 0.69, 95% CI 0.51-0.95; P = 0.023; I2 = 65.5%). No significant association was found for all-cause mortality (HR 0.95, 95% CI 0.88-1.02; P = 0.169). The 95% prediction interval for the primary outcome ranged from 0.37 to 1.39. Leave-one-out sensitivity analysis confirmed result stability. Egger's test showed no publication bias (P = 0.36).
Conclusion
Reversion from prediabetes to normoglycemia is associated with significant reductions in cardiovascular events and cardiovascular mortality, supporting early identification and management of prediabetes as a cardiovascular prevention strategy. The observational nature of the evidence and wide prediction interval warrant cautious interpretation.
INTRODUCTION
Dialysis patients with established atherosclerotic cardiovascular disease (ASCVD) face exceptionally high risks of mortality and recurrent cardiovascular events, yet remain substantially underrepresented in major statin trials. We aimed to synthesize evidence from studies restricted to this population to e...
K. Chienwichai, Pannawat Mongkolrattanakul, Arunchai Chang et al.· Kidney & Blood Pressure Rese...· 0 citations
BACKGROUND
Disruption in rest-activity rhythm (RAR) is an emerging risk factor for cardiovascular disease (CVD) and mortality, but the strength of evidence is unclear. Therefore, we conducted a systematic review and meta-analysis to assess associations between RAR characteristics and cardiovascular disease incidence or...
Feng-Shuo Chang, Jin-Hao Xu, M. Guo et al.· Journal of the American Hear...· 0 citations
Background Epidemiological research has indicated a potential association between the triglyceride-glucose (TyG) index and the risk of major adverse cardiocerebrovascular events (MACCE). Nevertheless, the precise nature and magnitude of this relationship remain to be fully elucidated. Objectives This study aims to asse...
Lei-Lei Liu, Ting-Ting Yang, Lin-Yuan Zhang et al.· Frontiers in Endocrinology· 0 citations
Prediabetes is a clinically relevant cardiometabolic state and its role as an independent CV therapeutic target remains uncertain, but future trials should address phenotype-specific risk stratification and evaluate contemporary cardiometabolic therapies in appropriately powered populations.
F. Biondi, S. Ghelardoni, E. Monti et al.· Atherosclerosis· 0 citations
Prediabetes is a critical phase that precedes the development of diabetes, characterized by insulin resistance as a key driver of its advancement. The estimated glucose disposal rate (eGDR) reflects insulin sensitivity, but its sex-specific prognostic value is uncertain.
We analyzed a prospective cohort of...
Ying Yang, Jing-Qi Yang, Yu-Na Du et al.· BMC Endocrine Disorders· 0 citations
Objective To compare cardiovascular and renal benefits and safety of GLP-1RAs, SGLT2is, and nsMRAs in T2D-CKD using network meta-analysis. Methods RCTs published through 7 August 2026 were systematically identified. A frequentist random-effects network meta-analysis was performed. Evidence certainty was assessed with C...
Hong-Li Chen, Xue-Jie Wu, M. Yuan et al.· Frontiers in Endocrinology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.